• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

ECDC: Communicable Disease Threats Report Week 10, 28 February to 6 March 2026

Commonground

Senior Moderator
This week’s topics

1. Overview of respiratory virus epidemiology in the EU/EEA

2. Middle East respiratory syndrome coronavirus (MERS-CoV) – Multi-country – Monthly update

3. SARS-CoV-2 variant classification

4. Mass gathering monitoring – Winter Olympic and Paralympic Games in Milan – 2026

5. Chikungunya virus disease – Mayotte, France – 2026



Executive Summary

Overview of respiratory virus epidemiology in the EU/EEA

· Summary: Primary care consultations for respiratory illness have returned to baseline levels

in more than half of reporting countries, indicating that respiratory virus circulation has

declined across much of the EU/EEA in recent weeks.

· Influenza virus circulation, while still widespread, continues to decrease in most countries,

with over half now reporting baseline or low intensity levels. Hospitalisations are also

decreasing, with adults 65 years old and above accounting for most admissions. Influenza

A(H3) remains the dominant subtype, followed by A(H1)pdm09.

· Respiratory syncytial virus (RSV) circulation remains high but has begun to slowly

decline. RSV hospitalisations appear to have peaked overall, but not in children under five

years old, who continue to account for most admissions.

· SARS-CoV-2 circulation remains low in all age groups, with very few hospitalisations reported.

· EuroMOMO reported all-cause mortality shows a declining trend in recent weeks across all

age groups, following a period of above-expected mortality from weeks 1–7 of 2026.


Middle East respiratory syndrome coronavirus (MERS-CoV) – Multi-country – Monthly update

• Since the previous update on 3 February 2026, and as of 2 March 2026, no new MERS cases

have been reported by the World Health Organization (WHO) or national health authorities.

• Since the beginning of 2026, and as of 2 March 2026, no MERS cases have been reported by

WHO or national health authorities.

• The probability of sustained human-to-human transmission among the general population in

Europe remains very low, and the impact of the disease in the general population is also

considered to be low. The current MERS-CoV situation poses a low risk to the EU/EEA.


SARS-CoV-2 variant classification

• Since the last update on 30 January 2026, and as of 27 February 2026, no changes have been

made to ECDC variant classifications for variants of concern (VOC), variants of interest (VOI),

variants under monitoring (VUM) or De-escalated variants.

• For this update, sufficient data for estimating variant proportions during the reporting weeks

were only available from two EU/EEA countries. Therefore, the statistics below only represent a

limited part of the EU/EEA.

• The VOI and VUM median proportions in the EU/EEA for weeks 6–7, 2026 were:

- BA.2.86 (VOI): 0.0% (range: 0.0–0.0%; interquartile range (IQR): 0.0–0.0%)

- NB.1.8.1 (VUM): 9.1% (range: 0.0–18.2%; IQR: 4.5–13.6%)

- XFG (VUM): 66% (range: 36.4–95.7%, IQR: 51.2–80.8%)

- BA.3.2 (VUM): 0% (range: 0.0–0%, IQR: 0.0–0%).


Mass gathering monitoring – Winter Olympic and Paralympic Games in Milan – 2026

• Since the previous update and as of 5 March, no major public health events related to

communicable diseases have been detected in the context of the Winter Olympic and

Paralympic Games.

• ECDC continues to monitor this event until 20 March. The Winter Paralympic Games Milano

Cortina 2026 start on 6 March 2026 and run until 15 March.

• The probability of EU/EEA residents becoming infected with communicable diseases during the

Winter Olympic and Paralympic Games 2026 is low, if general preventive measures are applied.


Chikungunya virus disease – Mayotte, France – 2026

• There is an intensification of chikungunya virus circulation in Mayotte, France, with over 270

cases reported since 1 January 2026.

• The current likelihood of chikungunya virus infection for travellers to Mayotte is moderate.

Travellers should be advised to take enhanced mosquito bite prevention measures. Vaccination

of travellers may be considered, based on national recommendations.

Continued: https://www.ecdc.europa.eu/sites/de...cable-disease-threats-report-week-10-2026.pdf
 
Back
Top